Susquehanna International Group
PDLI

Susquehanna International Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Susquehanna International Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,978
Closed -$160K – 12173
2020
Q3 		$160K Buy
50,978
+14,632
+40% +$46.7K ﹤0.01% 9642
2020
Q2 		$106K Sell
36,346
-13,375
-27% -$42.3K ﹤0.01% 9472
2020
Q1 		$140K Buy
49,721
+39,657
+394% +$128K ﹤0.01% 9058
2019
Q4 		$33K Sell
10,064
-90,202
-90% -$262K ﹤0.01% 9428
2019
Q3 		$217K Sell
100,266
-27,353
-21% -$73.1K ﹤0.01% 8937
2019
Q2 		$400K Buy
+127,619
New +$414K ﹤0.01% 7739
2019
Q1 		– Sell
-72,679
Closed -$245K – 10590
2018
Q4 		$211K Buy
+72,679
New +$200K ﹤0.01% 7640
2018
Q3 		– Sell
-116,523
Closed -$286K – 10942
2018
Q2 		$273K Buy
+116,523
New +$325K ﹤0.01% 8035
2018
Q1 		– Sell
-118,047
Closed -$324K – 10886
2017
Q4 		$324K Buy
118,047
+41,047
+53% +$126K ﹤0.01% 7465
2017
Q3 		$261K Hold
77,000
– – ﹤0.01% 7617
2017
Q2 		$190K Buy
77,000
+63,400
+466% +$146K ﹤0.01% 8336
2017
Q1 		$31K Sell
13,600
-267,105
-95% -$591K ﹤0.01% 8668
2016
Q4 		$595K Buy
+280,705
New +$783K ﹤0.01% 6621
2016
Q2 		– Sell
-47,941
Closed -$160K – 10071
2016
Q1 		$160K Sell
47,941
-58,593
-55% -$183K ﹤0.01% 8163
2015
Q4 		$377K Buy
106,534
+72,241
+211% +$302K ﹤0.01% 7291
2015
Q3 		$172K Sell
34,293
-102,220
-75% -$586K ﹤0.01% 8824
2015
Q2 		$878K Buy
136,513
+17,691
+15% +$119K ﹤0.01% 6487
2015
Q1 		$836K Buy
118,822
+67,421
+131% +$488K ﹤0.01% 6117
2014
Q4 		$396K Buy
51,401
+19,499
+61% +$154K ﹤0.01% 7668
2014
Q3 		$238K Sell
31,902
-62,799
-66% -$583K ﹤0.01% 8385
2014
Q2 		$916K Buy
94,701
+6,654
+8% +$59.3K ﹤0.01% 6234
2014
Q1 		$732K Sell
88,047
-724,479
-89% -$6.21M ﹤0.01% 6072
2013
Q4 		$6.86M Buy
812,526
+790,149
+3,531% +$6.66M ﹤0.01% 2505
2013
Q3 		$178K Buy
+22,377
New +$180K ﹤0.01% 7840

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Susquehanna International Group's PDLI Position: Q4 2020 in Review

Susquehanna International Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 50,978 shares — an estimated $160K sold.

Susquehanna International Group first reported a position in PDLI in Q3 2013 and held it in 24 quarters. The position peaked at $6.86M in Q4 2013. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Susquehanna International Group reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Susquehanna International Group sold 50,978 PDL BioPharma, Inc. shares in Q4 2020, an estimated $160K.
  • Susquehanna International Group first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 24 quarters.
  • Susquehanna International Group's PDL BioPharma, Inc. position peaked at $6.86M in Q4 2013.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Susquehanna International Group's 13F filing for Q4 2020, filed 16 Feb 2021.